KA
HALO icon

Kovack Advisors’s Halozyme HALO Stock Holding History

Kovack Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5
Closed -$230K – 470
2018
Q1 		$230K Buy
+5
New +$97 0.06% 387

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kovack Advisors's HALO Position: Q2 2018 in Review

Kovack Advisors sold out of Halozyme (HALO) in Q2 2018, closing a stake of 12,694 shares — an estimated $249K sold.

Kovack Advisors first reported a position in HALO in Q2 2017 and held it in 4 quarters. The position peaked at $363K in Q4 2017. 193 funds tracked by Wall St. Rank hold HALO as of Q2 2018.

  • Kovack Advisors reported no remaining Halozyme position as of Q2 2018 after selling out during the quarter.
  • Kovack Advisors sold 12,694 Halozyme shares in Q2 2018, an estimated $249K.
  • Kovack Advisors first reported a position in Halozyme in Q2 2017 and held it in 4 quarters.
  • Kovack Advisors's Halozyme position peaked at $363K in Q4 2017.
  • 193 funds tracked by Wall St. Rank held Halozyme as of Q2 2018.

Based on Kovack Advisors's 13F filing for Q2 2018, filed 1 Aug 2018.